This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health To Address One Of The Most Significant Needs In Men's Health With The Oncotype DX® Prostate Cancer Test

REDWOOD CITY, Calif., April 3, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the clinical trial results validating its biopsy-based Oncotype DX® prostate cancer test will be presented by investigators from the University of California, San Francisco (UCSF) in an oral session at the American Urological Association (AUA) Annual Meeting on May 8, 2013 in San Diego.  The presentation will also include the results of previously conducted development studies lead by Cleveland Clinic where researchers evaluated more than 700 patients and 700 candidate genes to select the genes for this test.

To view the multimedia assets associated with this release, please click:


The Oncotype DX prostate cancer test is designed to address one of the most significant needs in men's health by providing physicians and patients with a new way to assess the aggressiveness of a man's prostate cancer to enable a better informed course of care.

AUA Oral Presentation Details:
  • Date: Wednesday, May 8, 2013, 8:00-10:00 a.m. Pacific Time
  • Oral Presentation: "Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance" (Abstract #2131)
  • Presenter: Matthew R. Cooperberg, M.D., Assistant Professor of Urology; Epidemiology & Biostatistics, UCSF
  • Session Title: Prostate Cancer: Markers (I)
  • Location: San Diego Convention Center, 111 W. Harbor Drive, Room 1

Dr. Cooperberg and his colleagues at UCSF will present the important results of this independent, prospectively-designed clinical validation study that evaluated the Oncotype DX test in prostate needle biopsy specimens.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs